BACKGROUND: People with multiple sclerosis (pwMS) have an increased risk of infections; risk factors include underlying disease, physical impairment and use of some disease-modifying treatments. OBJECTIVE: To quantify changes in population-level infection rates among pwMS and compare these to the general population and people with rheumatoid arthritis (pwRA), and identify patient characteristics predictive of infections after MS diagnosis. METHODS: We conducted a multi-database study using data on 23,226 people with MS diagnosis from the UK Clinical Practice Research Datalink Aurum and GOLD (January 2000-December 2020). PwMS were matched to MS-free controls and pwRA. We calculated infection rates, and estimated incidence rate ratios (IRR) a...
PMCID: PMC3029296This is an open-access article distributed under the terms of the Creative Commons ...
Viral infections are probably involved in the pathogenesis of multiple sclerosis (MS). A recent coho...
BACKGROUND: Ocrelizumab safety outcomes have been well evaluated in clinical trials and open-label e...
BACKGROUND: People with multiple sclerosis (pwMS) have an increased risk of infections; risk factors...
Background and purpose: Multiple sclerosis (MS) patients are at increased infection risk. Here the i...
Infection in people with multiple sclerosis (MS) is of major concern, particularly for those receivi...
BackgroundMultiple sclerosis (MS) patients are at increased risk for infections. The aim of this stu...
Background: The disease-modifying therapies (DMTs) largely used in multiple sclerosis (MS) may resul...
Background: The disease-modifying therapies (DMTs) largely used in multiple sclerosis (MS) may resul...
This study is based in part on data from the Full Feature General Practice Research Database obtaine...
Background and objectives: Several studies have assessed risk factors associated with the severity o...
Objective: This study was undertaken to assess the impact of immunosuppressive and immunomodulatory ...
: Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum ...
Background: Multiple sclerosis (MS) appears to develop in genetically susceptible individuals as a r...
PMCID: PMC3029296This is an open-access article distributed under the terms of the Creative Commons ...
Viral infections are probably involved in the pathogenesis of multiple sclerosis (MS). A recent coho...
BACKGROUND: Ocrelizumab safety outcomes have been well evaluated in clinical trials and open-label e...
BACKGROUND: People with multiple sclerosis (pwMS) have an increased risk of infections; risk factors...
Background and purpose: Multiple sclerosis (MS) patients are at increased infection risk. Here the i...
Infection in people with multiple sclerosis (MS) is of major concern, particularly for those receivi...
BackgroundMultiple sclerosis (MS) patients are at increased risk for infections. The aim of this stu...
Background: The disease-modifying therapies (DMTs) largely used in multiple sclerosis (MS) may resul...
Background: The disease-modifying therapies (DMTs) largely used in multiple sclerosis (MS) may resul...
This study is based in part on data from the Full Feature General Practice Research Database obtaine...
Background and objectives: Several studies have assessed risk factors associated with the severity o...
Objective: This study was undertaken to assess the impact of immunosuppressive and immunomodulatory ...
: Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum ...
Background: Multiple sclerosis (MS) appears to develop in genetically susceptible individuals as a r...
PMCID: PMC3029296This is an open-access article distributed under the terms of the Creative Commons ...
Viral infections are probably involved in the pathogenesis of multiple sclerosis (MS). A recent coho...
BACKGROUND: Ocrelizumab safety outcomes have been well evaluated in clinical trials and open-label e...